Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed COO
|
|
Pharma-Bio Serv, Inc. (PBSV)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/31/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 03/17/2023 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year. Net income for the quarter ended January 31, 2023 was approximately $0.4 million, an increase of approximately $0.1 million when compared to the same period last year. "This quarter we were able to successfully maximize our resources in more profitable markets. This strategy yielded a positive effect on our overall g..." |
|
| 03/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 1, 2023 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for shareholders. The Special Dividend will be payable on or about April 14, 2023 to shareholders of record at the close of business on March 29, 2023. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life scie..." |
|
| 02/09/2023 |
8-K
| Quarterly results |
| 02/07/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Pharma-Bio Serv Retains Investment Banking Firm ACP Capital to Provide Investment Banking and M&A Advisory Services DORADO, PUERTO RICO / ACCESSWIRE / February 7, 2023 / Pharma-Bio Serv, Inc. , a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, announced today that it has retained ACP Capital Markets LLC for investment banking and M&A advisory services. ACP Capital Markets is a specialized investment bank focused on capital markets and advisory assignments. ACP’s capital markets unit specializes in private equity and debt placements while its M&A and Advisory practice is globally focused, covering both public and private marke..." |
|
| 01/30/2023 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / January 30, 2023 / Pharma-Bio Serv, Inc. , is a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries. Today, Pharma-Bio Serv announced that revenues for the year ended October 31, 2022 were approximately $19.4 million, a decrease of approximately $0.7 million when compared to last year. Additionally, net income for the year ended October 31, 2022 was approximately $1.0 million, an improvement of approximately $3.0 million when compared to last year. The net income variance is mostly due to the recording of an account receivable provision of approximately $5.2 million in 2021 which was partially of..." |
|
| 09/14/2022 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / September 14, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm providing services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2022 were approximately $4.8 and $14.8 million, respectively. This represents a decrease of approximately $0.2 million and an increase of $0.2 million, for three and nine months respectively, when compared to the same periods last year. Net income for the three and nine months ended July 31, 2022 was approximately $0.3 and $0.8 million, respectively, a decrease for both periods of approximately $2.0 million when compared to the sa..." |
|
| 06/24/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 03/17/2022 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2022 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2022 were approximately $5.0 million, an increase of approximately $0.5 million when compared to the same period last year. Net income for the quarter ended January 31, 2022 was approximately $0.3 million, reflecting no significant change when compared to the same period last year. “Our efforts to diversify and expand our geographical revenue should be noted in this quarter’s results. The continental US and Europe consulting markets represen..." |
|
| 02/14/2022 |
8-K
| Quarterly results |
| 11/15/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Pharma-Bio Serv Announces Special Dividend November 15, 2021 DORADO, PUERTO RICO / ACCESSWIRE / November 15, 2021 / Pharma-Bio Serv, Inc. , a regulatory, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of $0.075 per share for Shareholders. The Special Dividend will be payable on or about January 3, 2022 to shareholders of record at the close of business on December 15, 2021. Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting relat..." |
|
| 09/27/2021 |
8-K
| Other Events Interactive Data |
| 09/14/2021 |
8-K
| Quarterly results |
| 06/14/2021 |
8-K
| Quarterly results |
| 06/03/2021 |
8-K
| Quarterly results |
| 05/06/2021 |
8-K
| Quarterly results |
| 03/17/2021 |
8-K
| Quarterly results |
| 02/01/2021 |
8-K
| Quarterly results |
| 01/11/2021 |
8-K
| Quarterly results |
| 01/05/2021 |
8-K
| Quarterly results |
| 06/26/2020 |
8-K
| Quarterly results |
| 06/15/2020 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / June 15, 2020 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues for the three and six months ended April 30, 2020 were $5,648,000 and $10,261,000, respectively, an increase of approximately $498,000 and $545,000, or 9.7% and 5.6%, respectively, when compared to the same periods last year." |
|
| 04/29/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Loan Agreement of Pharma-Bio Serv PR, Inc. for Paycheck Protection Program Loan",
"Loan Agreement of Pharma Serv, Inc. for Paycheck Protection Program Loan",
"Loan Agreement of Pharma-Bio Serv US, Inc. for Paycheck Protection Program Loan",
"Paycheck Protection Program Note, executed by Pharma-Bio Serv PR, Inc",
"Paycheck Protection Program Note, executed by Pharma Serv, Inc",
"Paycheck Protection Program Note, executed by Pharma-Bio Serv US, Inc" |
|
| 03/16/2020 |
8-K
| Quarterly results |
| 01/29/2020 |
8-K
| Quarterly results |
| 12/27/2019 |
8-K
| Quarterly results |
| 10/28/2019 |
8-K
| Other Events, Financial Statements and Exhibits|
Docs:
|
"PHARMA-BIO SERV, INC. DECLARES CASH DIVIDEND DORADO, PUERTO RICO / ACCESSWIRE / October 28, 2019 / Pharma-Bio Serv, Inc. , today announced that its Board of Directors has declared a cash dividend of $0.075 per share. The dividend will be payable on or about November 15, 2019 to shareholders of record at the close of business on November 4, 2019. The Board will continue to evaluate the Company’s strategic plan, which might include future acquisitions, sales of business units, dividends or any combination of these opportunities while continuing our stock repurchase plan. "We are delighted to provide a dividend to our many longtime and loyal shareholders for the second time in as many years." said Victor Sanchez, CEO of Pharma-Bio Serv, Inc. About Pharma-Bio Serv, Inc. Pharma-Bio Serv is a co..." |
|
| 10/11/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/16/2019 |
8-K
| Quarterly results|
Docs:
|
"DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2019 / Pharma-Bio Serv, Inc. , a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues from continuing operations for the three and nine months ended July 31, 2019 were $5.0 and $14.7 million, respectively, an increase of approximately $0.3 and $2.6 million, or 7% and 21%, respectively, when compared to the same periods last year." |
|
| 06/14/2019 |
8-K
| Quarterly results |
| 05/29/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 03/18/2019 |
8-K
| Quarterly results |
| 01/29/2019 |
8-K
| Quarterly results |
|
|
|